Comparative Pharmacology
Head-to-head clinical analysis: GRANIX versus NIVESTYM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: GRANIX versus NIVESTYM.
GRANIX vs NIVESTYM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Granix (tbo-filgrastim) is a recombinant human granulocyte colony-stimulating factor (G-CSF) analog that binds to G-CSF receptors on hematopoietic progenitor cells, stimulating proliferation, differentiation, and release of neutrophils from the bone marrow.
Filgrastim is a recombinant human granulocyte colony-stimulating factor (G-CSF) that binds to G-CSF receptors on hematopoietic cells, stimulating proliferation, differentiation, and release of neutrophils from bone marrow.
5 μg/kg subcutaneously once daily for up to 7 days, or 5 μg/kg subcutaneously once daily for up to 14 days for stem cell mobilization.
5 mcg/kg subcutaneously or intravenously once daily for up to 14 days until absolute neutrophil count reaches 10,000/mm³ after nadir; or 5 mcg/kg subcutaneously once daily for 5 days for mobilization of peripheral blood progenitor cells.
None Documented
None Documented
Terminal half-life approximately 3.5 hours (range 1.8–5.4 h) in healthy subjects; clearance increases with neutrophil recovery due to G-CSF receptor-mediated uptake.
Terminal elimination half-life approximately 3.5 hours (subcutaneous) in healthy volunteers; in patients undergoing chemotherapy, half-life may be prolonged (up to 4-6 hours) due to neutrophil-mediated clearance.
Primarily renal excretion; neutrophil-mediated clearance. <1% unchanged in urine.
Primarily renal (via degradation to peptides and amino acids); <1% excreted unchanged. Biliary/fecal elimination is negligible.
Category C
Category C
Colony-Stimulating Factor
Colony-Stimulating Factor